Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study
Authors:
- 1 August 2015
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 73 (2) , 331-333.e1
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III studyJournal of the American Academy of Dermatology, 2014
- CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interactionClinical and Experimental Immunology, 2010
- Towards the Definition of a Chimpanzee and Human Conserved CD6 Domain 1 Epitope Recognized by T1 Monoclonal AntibodyHybridoma, 2008
- The long-term efficacy and safety of new biological therapies for psoriasisArchives of Dermatological Research, 2006